

Bringing in the Research Dollars! (BiRD)



Highlighting Pediatric Research Funding Opportunities

Brought to you by: The Emory+Children's Pediatric Research Center

Contact stacy.heilman@emory.edu with questions on the funding opportunities highlighted below or for general research grant application advice.

BiRD Highlights

- ❖ Opportunities to request funds for developing resources for [biomedical resources related to the mission of NIAID](#) and to [strengthen patient-centered outcomes research programs](#)
- ❖ Developing new and evaluate existing clinical trial outcome instruments/measures [to better assess treatments of diseases and injuries of interest to the NIAMS](#) and NINR funds to develop [innovative measurement tools for community engaged research efforts](#)
- ❖ OppNet offered RFA to fund new exploratory and developmental research projects investigating the [role of epigenetics in social, behavioral, environmental and biological relationships](#)
- ❖ R01 opportunities to study [mechanisms of adverse drug reactions in children](#) and how [inflammatory cytokines resulting from childhood obesity](#) can accelerate diseases associated with aging
- ❖ Improving healthcare cost and delivery through [Health Care Innovation Awards](#) designed to test new payment and service delivery models towards delivering better care and lowering healthcare costs and funds offered for [investigator-initiated research with a high potential to inform improvements to the U.S. health care system](#)
- ❖ [Career Development opportunities for GI researchers](#) and for [Cardiologists studying hypertension and/or peripheral vascular disease and research funding for Cardiology researchers interested in development of new devices and/or novel biologic therapies](#)
- ❖ Collaborative pilot funding opportunity sponsored by the [ACTSI](#)
- ❖ R01 and other funding opportunities for studying multiple aspects of [developmental disabilities and autism](#)
- ❖ Notices [highlighting AHRQ's interest in funding research to improve diagnostic performance in ambulatory care settings](#) and [NHLB's intent to fund the development and implementation of point-of-care technologies](#)

Program/Link	NIAID Resource-Related Research Projects (R24) http://grants.nih.gov/grants/guide/pa-files/PA-13-242.html
Purpose	<p>Requests submission of investigator-initiated Resource-Related Research Projects (R24) applications. The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified.</p> <p>The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated research projects that will develop resources to serve biomedical research. A resource is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making the most timely, high quality, and cost-efficient progress in a field. The resource should be available to any qualified investigator, and should be highly quality controlled, replenishable, and not duplicate resources available commercially or through other sources.</p>
Funds Available	Application direct costs budgets are not limited, but need to reflect actual needs of proposed resource. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. A project period of up to 5 years may be requested.
Deadline	Standard NIH Deadlines*
Remarks	<ul style="list-style-type: none"> ➤ As a first step, potential applicants are highly encouraged to contact the Scientific/Research Contact listed below for clarification on the scope of this FOA, programmatic priorities, or other questions related to the submission and review of an application. ➤ Funds for these projects are extremely limited and the Institute does not expect to make more than 1-2 competing awards per year. ➤ The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.

Program/Link	Infrastructure Development Program in Patient-Centered Outcomes Research (PCOR) (R24) http://grants.nih.gov/grants/guide/pa-files/PA-12-114.html
Purpose	The overall goals of this FOA are to: 1) provide faculty/research staff methodological expertise in CER through the conduct of research projects and other professional development activities; and 2) strengthen the underlying institutional infrastructure needed to support PCOR research, as defined in this FOA. The core infrastructure activities should be designed to support not only the proposed work, but also allow the future development and conduct of additional projects and activities with other funding sources and partners.

Funds Available	Applications may be up to five years in duration with a budget supported by AHRQ not to exceed \$1 million per year in total costs to the government. Facilities and administrative (F&A) costs requested by applicants are included in the total cost limitation. Applications with project periods that exceed five years or budgets that exceed \$1 million total costs in any given year will not be reviewed. Infrastructure components of applications should constitute at least ½ of the total projected budget costs. Applicants must propose between 3 and 5 multi-year research projects. Total costs for each research project must not exceed \$250,000 annually. Budgets associated with stakeholders or inter-organizational partnerships with existing centers of excellence cannot exceed 1/3 of the total average annual total costs.
Deadline	12/19/13* and 12/19/14 *For applicants intending to submit an application for the December 2013 receipt date, a request for permission to submit an application letter must be received by AHRQ by Wednesday, July 31, 2013.
Remarks	<ul style="list-style-type: none"> ➤ A minimum time commitment of 1.8 calendar months (i.e. 15%) annual effort is required from the PD/PI ➤ This FOA seeks to provide support to institutions which currently have <i>some</i> existing health services research capacity related to the mission of AHRQ, however, they cannot be centers of excellence in comparative effectiveness research or possess investigators who currently receive large-scale research support from such components as AHRQ or NIH in comparative effectiveness research. <i>The required advanced permission step outlined in the FOA will verify eligibility in this regard.</i>

Program/Link	NIAMS Clinical Trial Outcome Instrument Development Grant Program (U01) http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-14-008.html
---------------------	---

Purpose	For research awards designed to develop new and evaluate existing clinical trial outcome instruments/measures to better assess the benefits (efficacy and effectiveness) and adverse impacts of therapies employed to treat diseases and injuries of interest to the NIAMS. This FOA seeks to facilitate the development and subsequent evaluation of both new and existing clinically relevant and patient-important outcome instruments/measures that could be further tested in existing or novel clinical trials designed to gain widespread acceptance and application in the diagnosis, monitoring, treatment or cure of diseases and injuries of interest to the NIAMS. Outcome instruments/measures should be as generalizable as possible with the ultimate aim to impact patient care.
----------------	--

Suggested topics may include, but are not limited to:

- The testing of preliminary improvement or worsening of adult and juvenile disease endpoints.
- The utilization of new/improved outcome instruments/measures to evaluate disease damage and or the interaction with other clinically-relevant patient-important outcomes.
- Objective outcome instruments/measures (e.g., biomarkers, imaging modalities) to functionally assess the early progress/success of

interventions intended to prevent or cure diseases (e.g., tissue-engineering).

- Outcome instruments/measures based on emerging technologies intended to evaluate response to diagnostic procedures and non-operative and operative treatments.
- Improvement of PROs intended to assess symptoms and/or health-related quality of life measures in the context of chronic rheumatic, bone, joint, ligament/tendon, muscle and skin diseases, illnesses and injuries in adult and pediatric patients.
- Development of efficient state-of-the-art methods (including mobile or wireless methods) for collection of a common core set of benefits or adverse events that could ensure more uniform reporting and comparison of these outcome instruments/measures in real world, interventional or observational trials.
- Approaches that allow the combined analyses of data from multiple trials to establish, test and/or validate outcome instruments/measures that assess disease progression and individual patient responses to therapeutics.
- Approaches to facilitate the updating, sharing and disseminating of trial data, current core set measure forms, and uniform data collection procedures.
- Identification, assessment and use of existing databases to analyze and test novel outcome instruments/measures.

Funds Available An applicant may request a budget for up to \$150,000 in direct costs per year for up to 3 years

Deadline 2/7/14

Remarks ➤ See this link for information on illnesses and injuries of interest to the NIAMS http://www.niams.nih.gov/About_Us/Mission_and_Purpose/default.asp

Program/Link **Innovative Measurement Tools for Community Engaged Research Efforts (R01)**
<http://grants.nih.gov/grants/guide/pa-files/PA-13-209.html>

Purpose This funding opportunity announcement issued by the National Institute of Nursing Research (NINR) seeks to develop innovative measurement tools for community engaged research efforts.

Specific areas of research interest include, but are not limited to:

- Develop and test tools that measure trust between partners in engagement efforts
- Develop and test tools that measure capacity/readiness for research efforts
- Develop and test tools to measure successful partnership/collaboration in engagement efforts
- Develop reliable and valid tools that can be used in measuring community engaged research efforts that impact individual outcomes such as trust, capacity, empowerment, and collaboration
- Use established statistical procedures to test existing or newly developed

- instruments
- Develop and test instruments that measure the success or failure of partnership efforts
- Apply existing tools in measuring community engaged research efforts
- Develop and test scientific measures of sustainability for health improvement programs
- Develop and test scientific outcome measures related to improving health disparities

Funds Available Application budgets are not limited, but need to reflect the actual needs of the proposed project. Maximum project period is 5 years.

Deadline Standard NIH Deadlines*

Remarks ➤ Applicants are encouraged to apply and draw on the foundation provided by the CTSA (i.e. ACTSI).

Program/Link **Research on the Role of Epigenetics in Social, Behavioral, Environmental and Biological Relationships, throughout the Life-Span and across Generations (R21)**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-TW-13-002.html>

Purpose Encourages exploratory and developmental grant applications to lay the foundation for innovative and collaborative basic research on the role of epigenetics in social, behavioral, environmental and biological relationships, throughout the life-span and across generations. Research plans that are responsive to this FOA will use existing bio-psycho-social and environmental data from human cohorts or animal studies that have biospecimens available for epigenetic profiling. The one year exploratory/developmental awards are expected to generate preliminary data for comprehensive basic research applications to study interactions between epigenetics and social/behavioral/biological/environmental factors in both normal function and pathophysiology throughout life and across generations. The results may ultimately inform research to develop clinical decision/diagnostic tools and prevention/treatment strategies.

Funds Available Up to \$150,000 may be requested per application for a maximum project period of 1 year

Deadline 11/13/13

Remarks ➤ This FOA is sponsored by NIH Basic Behavioral & Social Science Opportunity Network ([OppNet](#)) on behalf of its constituent organizations; All 24 NIH Institutes and Centers that fund research and four Program Offices within the NIH Office of the Director (ICOs) co-fund and co-manage OppNet.

➤ The R21 mechanism is intended to encourage new exploratory and developmental research projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area. By using the R21 mechanism, the NIH seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets, and technologies that have the

potential to substantially advance biomedical, behavioral, or clinical research.

Program/Link	Mechanisms of Adverse Drug Reactions in Children (R01) http://grants1.nih.gov/grants/guide/pa-files/PAR-11-051.html
Purpose	Encourages projects that enhance the state-of-the-science on the molecular and cellular, genetic and epigenetic mechanisms involved in the production of adverse drug reactions in children. The objective of this announcement includes research on the role of ontogeny and the characterization of pharmacogenetic and developmental variations of drug metabolizing enzymes (DMEs), transporters, ion channels, receptors and signaling pathways that are responsible for drug toxicity in the pediatric population.
Funds Available	Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total project period may not exceed 5 years.
Deadline	Standard NIH Deadlines*
Remarks	➤ Companion FOA – R03 Small Grant Program http://grants1.nih.gov/grants/guide/pa-files/PAR-11-052.html

Program/Link	Chronic Inflammation and Age-related* Disease (R01) http://grants.nih.gov/grants/guide/pa-files/PAR-13-233.html
Purpose	The participating NIH Institutes and Centers invite applications to address both the origins and the effects of low level chronic inflammation in the onset and progression of age-related diseases and conditions. Chronic inflammation, as defined by elevated levels of both local and systemic cytokines and other pro-inflammatory factors, is a hallmark of aging in virtually all higher animals including humans and is recognized as a major risk factor for developing age-associated diseases. The spectra of phenotypes capable of generating low-level chronic inflammation and their defining mediators are not clear. Further, a clear understanding of how chronic inflammation compromises the integrity of cells or tissues leading to disease progression is lacking. The role of dietary supplements and/or nutritional status in chronic inflammation in age-related disease is also poorly studied. Thus, there is a critical need to establish the knowledge base that will allow a better understanding of the complex interplay between inflammation and age-related diseases. Applications submitted to this FOA should aim to clarify the molecular and cellular basis for the increase in circulating inflammatory factors with aging, and/or shed light on the cause-effect relationship between inflammation and disease, using pre-clinical (animal or cellular based) models.
Funds Available	For all participating ICs, with the exception of NHLBI, application budgets are not limited, but need to reflect the actual needs of the proposed project. Maximum project period is 5 years. NHLBI will not accept applications requesting \$500,000 or more in direct costs in any year.

Deadline Standard NIH Deadlines*

Remarks ➤ ***NICHD is participating in the call** based on an interest in how the inflammatory cytokines generated by adipocytes and by macrophages embedded in the fat mass as a result of **childhood obesity** can accelerate the appearance of diseases associated with aging, especially T2DM, now commonly seen in adolescence, and atherosclerotic plaques in the third decade.

Program/Link **CMS Health Care Innovation Awards Round Two**
<http://innovation.cms.gov/initiatives/Health-Care-Innovation-Awards/Round-2.html>

Purpose Under this announcement, CMS will spend up to \$1 billion for awards and evaluation of projects from across the country that test new payment and service delivery models that will deliver better care and lower costs for Medicare, Medicaid, and Children’s Health Insurance Program (CHIP) enrollees. The second round of the Health Care Innovation Awards will support public and private organizations in four defined areas that have a high likelihood of driving health care system transformation and delivering better outcomes. Specifically, in this second round, CMS is seeking proposals in the following 4 categories:

1. Models that are designed to rapidly reduce Medicare, Medicaid, and/or CHIP costs in outpatient and/or post-acute settings.
2. Models that improve care for populations with specialized needs.
3. Models that test approaches for specific types of providers to transform their financial and clinical models.
4. Models that improve the health of populations – defined geographically (health of a community), clinically (health of those with specific diseases), or by socioeconomic class – through activities focused on engaging beneficiaries, prevention (for example, a diabetes prevention program or a hypertension prevention program), wellness, and comprehensive care that extend beyond the clinical service delivery setting.

Funds Available CMS estimates that there will be approximately 100 awards, with a range of approximately \$1 million to \$30 million per award. Project period is expected to be 3 years per award.

Deadline MANDATORY LOI due June 28, 2013 3pm EDT
Applications due August 15, 2013 3pm EDT

Remarks ➤ Models that primarily focus on acute hospital inpatient care are excluded from this round and will not be reviewed. (Hospitals are eligible to apply for awards if they propose a model within one of the four Innovation Categories described in the announcement)

➤ In this round, CMS specifically seeks new payment models to support the service delivery models funded by this initiative. All applicants must submit, as part of their application, the *design* of a payment model that is consistent with the new service delivery model that they propose.

- Children’s Healthcare of Atlanta and GA Tech are considering submitting an application in response to this FOA. If you are interested in learning more about this effort, contact ed.price@gatech.edu

Foundation

Program/Link **National Institute for Health Care Management Foundation Research Grants**
<http://nihcm.org/grants/research-grants>

Purpose To support investigator-initiated research with high potential to inform improvements to the U.S. health care system by reducing health spending growth, enhancing quality, and/or expanding access to health insurance and health care services. Projects must advance existing knowledge in the areas of health care financing, delivery, management and/or policy.

Funds Available Up to \$150,000

Deadline Three page letter of inquiry due 7/19/13 by 5pm
 Upon invitation, full proposals due Sept 2013

Remarks ➤ Expect to make 3 awards

Research Training & Career Development

Program/Link **American Gastroenterological Association Research Scholar Award**
<http://www.gastro.org/aga-foundation/grants/career-development-awards/research-scholar-awards>

Purpose The overall objective of the Research Scholar Award (RSA) is to enable young investigators to develop independent and productive research careers in digestive diseases by ensuring that a major proportion of their time is protected for research. The recipient will be selected based on the following criteria: significance, investigator, innovation, approach, environment, relevance to AGA’s mission and evidence of institutional commitment. The candidate should state clearly how the additional training will benefit his/her research career.

Funds Available \$90K per year for two years

Deadline 10/18/13

Remarks

- This award will support young faculty (not fellows) who have demonstrated exceptional promise and have some record of accomplishment in research. Candidates should be in the beginning years of their careers; therefore, established investigators are not appropriate candidates
 - MD applicants – no more than 5 years out from clinical training
 - PhD applicants – no more than 5 years out from PhD award
- For a complete list of AGA Research Foundation Grants, visit <http://www.gastro.org/aga-foundation/grants>

Program/Link **American College of Cardiology Research & Career Development Awards**

<http://www.cardiosource.org/ACC/About-ACC/Awards-Program/Research-and-Career-Development-Awards.aspx>

Purpose	<p>ACCF/William F. Keating, Esq. Endowment Career Development Award To encourage junior faculty in the early phases of their careers in the field of cardiology. The award will provide one junior faculty member with a year of research support. Preference will be given to applications focusing on hypertension and/or peripheral vascular disease. Eligible applicants are no more than five years out of training.</p> <p>ISCTR-ACCF Cardiovascular Translational Research Scholarship To enable the awardee to expedite scientific discovery to clinical application, ultimately benefitting the patient and society by providing science earlier and decreasing the developmental costs related to new devices and/or novel biologic therapies. The program will cover the topics of:</p> <ul style="list-style-type: none">• Basic science• Preclinical science• Clinical science and trial design• Regulatory pathways (FDA) for IND (investigational new drug application) and IDE (investigational new device exemption) <p>The emphasis will be on biologics (stem cell therapy and genomics) and cardiovascular device development. Applicants must have completed one year of previous interventional cardiology.</p>
Funds Available	<p>ACCF/William F. Keating, Esq. Endowment Career Development Award: \$70,000 salary support for one year of research</p> <p>ISCTR-ACCF Cardiovascular Translational Research Scholarship: \$60,000 salary support for one year of research</p>
Deadline	9/23/13
Remarks	➤ The submission site for applications will open this summer

Pilot/Seed Fund Opportunities

Program/Link	<p>ACTSI Multi-Institutional Translational Pilot Program http://www.actsi.org/areas/pilot_grants/documents/Multi-Institutional%20Pilot%20RFA_Final.pdf</p>
Purpose	<p>One primary focus of the ACTSI is to orchestrate the advancement, selection, and funding of promising new technology through its Research Technologies Program. This Multi-Institutional Translational Pilot Program is intended to accelerate the development, validation, and translation of new biomedical technologies. Review criteria include scientific merit, alignment with the goals of the ACTSI, potential health care impact and significance and the potential for successfully obtaining further financial support leading to commercialization or extramural funding.</p>
Funds Available	Up to \$50K per PI/institution for a one-year period for a total project cost of no

more than \$150K direct costs

Deadline

LOI must be submitted to lburr@emory.edu by 7/1/13
Full proposals due by 7/15/13

Remarks

- This is a multiple-PI grant, where one PI from each of the 3 institutions is required
 - One PI must be from the Wallace H. Coulter Dept of BME at GA Tech and Emory University
 - Must be two additional PI's, faculty in the professorial ranks or a clinical researcher with patient contact, one from Emory SOM and one from MSM

Special Interest – Autism and Intellectual Disabilities

Program/Link Outcome Measures for Use in Treatment Trials for Individuals with Intellectual and Developmental Disabilities (R01)
<http://grants.nih.gov/grants/guide/pa-files/PAR-13-213.html>

Purpose Encourages Research Project Grant (R01) applications from institutions/organizations that propose to develop, validate, and/or calibrate informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities (IDD). This FOA will address a significant need in the field, one that is especially apparent in efforts to develop pharmacological treatments for these populations.

Funds Available Budgets for direct costs of up to \$499,999 per year may be requested for a maximum of \$2,499,996 direct costs over a five-year project period.

Deadline Standard NIH Deadlines*

Remarks ➤ Multidisciplinary teams that consist of an appropriate combination of: 1) researchers experienced in the conduct of behavioral, social emotional, educational and cognitive studies of children with IDD; 2) scientists with knowledge of neurological and/or physiological basis of the disorder; 3) researchers experienced in conducting clinical trials; 4) researchers experienced in the design of psychometric and/or medical assessments, and; 5) clinicians who treat individuals with IDD(s) are encouraged to apply.

Program/Link Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01)
<http://grants.nih.gov/grants/guide/pa-files/PAR-13-195.html>

Purpose Encourages applications that propose to identify, validate and/or calibrate physiologic and/or behavioral measures in preclinical animal models of disorders associated with intellectual and developmental disabilities (IDD), particularly in the pediatric population. It specifically targets the development of outcome measures or biomarkers that can serve as informative endpoints in preclinical trials of therapeutic compounds and will predict the safety and efficacy of interventions in human clinical trials for these disorders. This FOA will focus ongoing clinical and translational research on a neglected area essential for therapy and pharmacological treatment development.

Funds Available	Budgets for direct costs of up to \$499,999 per year may be requested and project period may not exceed 5 years.
Deadline	Standard NIH Deadlines*
Remarks	➤ See the FOA for the specified core set of reporting standards that must be addressed within the application

Program/Link	Research on Autism Spectrum Disorders (R01) http://grants.nih.gov/grants/guide/pa-files/PA-13-216.html
Purpose	Encourages research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism spectrum disorders (ASD). Basic, clinical, and applied studies are encouraged.
Funds Available	Application budgets are not limited, but need to reflect the actual needs of the proposed project. Total project period may not exceed 5 years.
Deadline	Standard NIH Deadlines*
Remarks	➤ Companion FOA's: <ul style="list-style-type: none"> ○ R21 Exploratory/Developmental Grant - http://grants.nih.gov/grants/guide/pa-files/PA-13-217.html ○ R03 Small Grant Program – http://grants.nih.gov/grants/guide/pa-files/PA-13-218.html

Notices:

AHRQ Announces Interest in Research to Improve Diagnostic Performance in Ambulatory Care Settings

NOT-HS-13-009

<http://grants.nih.gov/grants/guide/notice-files/NOT-HS-13-009.html>

With this notice, AHRQ is providing information about one of its highest research priorities for investigator initiated applications. This includes gaining a better understanding of the incidence, cost, determinants, and strategies for preventing or mitigating diagnostic errors (i.e., misdiagnosis, missed diagnosis, delayed diagnosis). For the purposes of this SEN, ambulatory care refers to health care provided in emergency departments; clinicians' offices and practices, both large and small; outpatient clinics; community health centers; urgent care centers; and ambulatory surgery centers.

Use of Multiple Funding Mechanisms. AHRQ will use standing grant mechanisms such as the R01, R03, R18, and K08 funding mechanisms to support research on diagnostic errors. The relevant general AHRQ Funding Opportunity Announcements for R01, R18, R03, and K08 mechanisms can be found at: <http://www.ahrq.gov/funding/research/announcements/index.html>.

Notice of Intent to Publish a Funding Opportunity Announcement for Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point-of-Care SBIR (R43/R44)

NOT-HL-13-176

<http://grants.nih.gov/grants/guide/notice-files/NOT-HL-13-176.html>

The National Heart, Lung, and Blood Institute intends to publish a new Funding Opportunity Announcement (FOA) that will encourage applications for research in support of development of novel point-of-care (POC) and implementation of existing technologies specifically for practical clinical applications which can guide diagnostic and therapeutic efforts in the heart, lung, blood, and sleep clinical research settings.

Among the areas of research encouraged in this initiative are evidence of the development and validation of the POC tool/technology (new or repurposed), including software development as necessary (Phase I), with subsequent feasibility testing in clinical studies (Phase II). In addition, the research should include an integrated system(s) or components that can be easily integrated into existing systems. Also, collaborative investigations combining expertise in clinical trials and regulatory requirements using POC devices in the areas of heart, lung, blood and sleep research will be encouraged and these investigators should also begin considering applying for this application.

The FOA is expected to be published in Summer 2013 with an expected application due date in Fall 2013. ***This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.***

This Notice specifically encourages investigators with expertise and insights in the area of POC tools and technology that could enhance clinical trials in the area of heart, lung, blood, and sleep research to begin to consider applying for this new FOA.

Also see <http://grants.nih.gov/grants/guide/notice-files/NOT-HL-13-177.html> for R41/R42 related notice.

*NIH STANDARD DUE DATES CITED ABOVE

Mechanism(s)	Cycle I Due Date	Cycle II Due Date	Cycle III Due Date
P Series ALL – new, renewal, resubmission, revision	25-Jan	25-May	25-Sept
R01 NEW <i>renewal, resubmission, revision</i>	5-Feb <i>5-Mar</i>	5-Jun <i>5-Jul</i>	5-Oct <i>5-Nov</i>
G12, M01, R10/U10, R24, R24/U24, S06, U19, U45, U54, U56 <i>All - new, renewal, resubmission, revision</i>	25-Jan	25-May	25-Sept
R41, R42, R43, R44, U43, U44, <i>All - new, renewal, resubmission, revision</i>	5-April	5-Aug	5-Dec
R03, R21, R34 NEW <i>renewal, resubmission, revision</i>	16-Feb <i>16-Mar</i>	16-Jun <i>16-Jul</i>	16-Oct <i>16-Nov</i>
K series NEW <i>renewal, resubmission, revision</i>	12-Feb <i>12-Mar</i>	12-Jun <i>12-Jul</i>	12-Oct <i>12-Nov</i>
All AIDS and AIDS-Related Applications (for mechanisms cited above) <i>All - new, renewal, resubmission, revision</i>	7-May	7-Sept	7-Jan

For the full schedule of NIH standard due dates, see
<http://grants1.nih.gov/grants/funding/submissionschedule.htm>



ABOUT THE BIRD:

This compilation of general interest funding opportunities and announcements with possible collaborative potential is distributed to our pediatric research community. It is compiled by the Emory-Children's Pediatric Research Center to disseminate funding announcements of potential interest in a consolidated manner. More specific announcements are distributed in a more targeted fashion.

If you are not receiving this directly from Stacy Heilman and wish to be added to our Pediatric Research listserv, please e-mail stacy.heilman@emory.edu to make the request. Please also contact Stacy if you are interested in applying for any pediatric focused research funding opportunities and/or if you are interested in building collaborative efforts and programs towards applying for future pediatric research funding.